Transfer-pricing treatment of ITeS margins excludes pass-through tax recoveries and separate delayed-receivables interest after working-capital adjust...
Capacity-utilisation adjustments under TNMM can neutralise substantiated COVID-related idle costs where underutilisation materially affects profitabil...
TNMM functional comparability requires excluding rice manufacturers from a pure Basmati rice trader's benchmark and recognising operating export recei...
Working-capital adjustment subsumes delayed-receivable effects in TNMM benchmarking of captive software-development services, avoiding separate notion...
Transfer-pricing comparability requires exclusion of financially illogical super-profit comparables and correction of unsupported annual-report and ma...
Charitable character assessment preserves Section 80G approval despite inclusive spiritual teachings and incidental religious expenditure within the s...
Penalty proceedings for cash-loan acceptance require assessment proceedings and recorded Assessing Officer satisfaction; absent these, the proceedings...
Page of 4828
Press 'Enter' after typing page number.
161 to 180 of 96556 Results
❮
❯
❯❯
0 / 200
Expand Note
Add to Folder
No Folders have been created
+
Are you sure you want to delete "My most important" ?
Various issues related to allowability of expenses, deductions, transfer pricing adjustments, and other income tax matters for a pharmaceutical company. Key points are: Expenses incurred in providing freebies to doctors are disallowed u/s 37(1) retrospectively from 14-12-2009 as per MCI regulations and CBDT circular. Disallowance restricted to 5% of business advancement and sales promotion expenses, and entire doctor sponsorship expenses disallowed. Employee PF/ESI contribution disallowed for late deposits. Deductions u/ss 80-IC and 80-IE allowed for certain incomes like notice pay, scrap sale, service tax refund, miscellaneous income, export benefits, insurance claims, forex gains, cash discounts. Interest income eligible after excluding related expenses. Government biotechnology grant not connected to eligible units, hence disallowed. Administrative expenses allocated based on human resources instead of turnover. Leave encashment provision disallowed u/s 43B, allowed on actual payment. Weighted deduction u/s 35(2AB) allowed for certain R&D expenses like clinical trials, product registration, interest, labor charges, furniture, electrical equipment. Disallowance u/s 14A not added to book profits under 115JB. Transfer pricing adjustments: No adjustment for corporate guarantee fee already offere.
Various issues related to allowability of expenses, deductions, transfer pricing adjustments, and other income tax matters for a pharmaceutical company. Key points are: Expenses incurred in providing freebies to doctors are disallowed u/s 37(1) retrospectively from 14-12-2009 as per MCI regulations and CBDT circular. Disallowance restricted to 5% of business advancement and sales promotion expenses, and entire doctor sponsorship expenses disallowed. Employee PF/ESI contribution disallowed for late deposits. Deductions u/ss 80-IC and 80-IE allowed for certain incomes like notice pay, scrap sale, service tax refund, miscellaneous income, export benefits, insurance claims, forex gains, cash discounts. Interest income eligible after excluding related expenses. Government biotechnology grant not connected to eligible units, hence disallowed. Administrative expenses allocated based on human resources instead of turnover. Leave encashment provision disallowed u/s 43B, allowed on actual payment. Weighted deduction u/s 35(2AB) allowed for certain R&D expenses like clinical trials, product registration, interest, labor charges, furniture, electrical equipment. Disallowance u/s 14A not added to book profits under 115JB. Transfer pricing adjustments: No adjustment for corporate guarantee fee already offere.
Note: It is a system-generated summary and is for quick reference only.